Erratum: Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial (Lancet (2014) 384 (403-13))

M. Manns; P. Marcellin; F. Poordad

doi:10.1016/S0140-6736(16)30324-5

Erratum: Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial (Lancet (2014) 384 (403-13))

M. Manns, P. Marcellin, F. Poordad

Transplant Center

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	1816
Number of pages	1
Journal	The Lancet
Volume	387
Issue number	10030
DOIs	https://doi.org/10.1016/S0140-6736(16)30324-5
State	Published - Apr 30 2016

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/S0140-6736(16)30324-5

Cite this

Manns, M., Marcellin, P., & Poordad, F. (2016). Erratum: Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial (Lancet (2014) 384 (403-13)). The Lancet, 387(10030), 1816. https://doi.org/10.1016/S0140-6736(16)30324-5

Erratum : Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial (Lancet (2014) 384 (403-13)). / Manns, M.; Marcellin, P.; Poordad, F.

In: The Lancet, Vol. 387, No. 10030, 30.04.2016, p. 1816.

Research output: Contribution to journal › Comment/debate › peer-review

Manns, M, Marcellin, P & Poordad, F 2016, 'Erratum: Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial (Lancet (2014) 384 (403-13))', The Lancet, vol. 387, no. 10030, pp. 1816. https://doi.org/10.1016/S0140-6736(16)30324-5

Manns M, Marcellin P, Poordad F. Erratum: Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial (Lancet (2014) 384 (403-13)). The Lancet. 2016 Apr 30;387(10030):1816. https://doi.org/10.1016/S0140-6736(16)30324-5

@article{b1324b958ea642e5b6d054d3a0400392,

title = "Erratum: Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial (Lancet (2014) 384 (403-13))",

author = "M. Manns and P. Marcellin and F. Poordad",

year = "2016",

month = apr,

day = "30",

doi = "10.1016/S0140-6736(16)30324-5",

language = "English (US)",

volume = "387",

pages = "1816",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10030",

}

TY - JOUR

T1 - Erratum

T2 - Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial (Lancet (2014) 384 (403-13))

AU - Manns, M.

AU - Marcellin, P.

AU - Poordad, F.

PY - 2016/4/30

Y1 - 2016/4/30

UR - http://www.scopus.com/inward/record.url?scp=84968860935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84968860935&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(16)30324-5

DO - 10.1016/S0140-6736(16)30324-5

M3 - Comment/debate

AN - SCOPUS:84968860935

VL - 387

SP - 1816

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10030

ER -

Erratum: Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial (Lancet (2014) 384 (403-13))

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this